Fact checked byKristen Dowd

Read more

September 26, 2023
1 min read
Save

ALK-Abelló withdraws lot of pecan nut allergen extract

Fact checked byKristen Dowd
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Key takeaways:

  • ALK-Abelló has voluntarily withdrawn lot #00396391 of its pecan nut allergen extract.
  • This lot was implicated in false-negative skin test results, with subsequent anaphylaxis.
Perspective from Cosby A. Stone Jr., MD, MPH

ALK-Abelló has voluntarily withdrawn lot No. 0003963971 of its pecan nut allergen extract due to false-negative skin test results, including a case of life-threatening anaphylaxis, according to an FDA MedWatch alert.

The lot includes 5 mL vials of the pecan nut (Carya illinoinensis) allergen extract with 1:10 5STV concentrations and an expiration date of Feb. 4, 2024. The FDA encourages providers to examine their stock immediately to determine if they have any vials from this lot.

pecans
A case of life-threatening anaphylaxis followed a false-negative skin test result for pecan nut allergy with extract lot No. 00396391 from ALK-Abelló. Image: Adobe Stock

Providers that have products from this lot should cease their use immediately and contact the manufacturer’s sales support department at (800) 325-7354 to return the affected product and receive a replacement.

In February 2023, the FDA approved safety labeling changes to the warnings and precautions section of the prescribing information for all allergenic extracts used in food allergy diagnosis indicating that false-negative skin test results had been reported during post-marketing diagnostic use of some extracts.

Considering associations between these false-negative skin test results and anaphylaxis from subsequent exposure to allergens, the FDA advised providers to consider confirming negative skin tests with serologic testing based on patient clinical histories and indices of suspicion.

These changes were prompted by reports of false-negative skin test reports following use of certain lots of ALK-Abelló’s peanut allergen extract, which also included associations with life-threatening anaphylaxis following subsequent exposure to peanut.

Also, the FDA reminded providers and patients to report adverse events or side effects related to the use of these products to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program online or at (800) 332-1088.